Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behcet's disease with parenchymal involvement: presentation of four cases

Shugaiv E., Tuzun E., Mutlu M. O., Kiyat-Atamer A., Kurtuncu M., Akman-Demir G.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, sa.4, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Basım Tarihi: 2011
  • Dergi Adı: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: mycophenolate mofetil, Behcet's disease, parenchymal neuro-Behcet's disease, immunosuppression, autoimmunity, NEUROLOGICAL INVOLVEMENT, UVEITIS
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background. Behcet's disease is a inultisystemic, relapsing, inflammatory disorder of unknown origin. Among Turkish cohorts, 5-15% of patients show involvement of the central nervous system (CNS) at some time during their disease. There, are mainly two types of clinical presentation: parehchymal CNS inflammation manifesting mainly as meningoencephalitis of the brainstem, or dural sinus thrombosis. Several drugs like high-dose steroids or immunosuppressive agents, mainly azathioprine, are used in the treatment. For patients who do not respond sufficiently to these agents or are not able tolerate them, other options are needed. Patients. We are presenting 4 cases with parenchymal neuro-Behcet's disease, where commonly used immunosuppressive drugs could not be continued due to intolerance or inefficacy. However, the patients benefited well from mycophenolate mofetil. The benefit was sustained during 3-7 years of follow-up (median 6.5 years). Conclusion. Mycophenolate mofetil seems to be an alternative drug in parenchymal neuro-Behcet's disease; however, large controlled studies should be performed for verification of our results.